DMSI Stock Overview
Dermisonics, Inc. manufactures ultrasonic transdermal drug-delivery technologies and equipment.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Dermisonics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000025 |
| 52 Week High | US$0.001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | -75.00% |
| 3 Year Change | -75.00% |
| 5 Year Change | -98.21% |
| Change since IPO | -99.99% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| DMSI | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 0% | -0.9% | -0.7% |
| 1Y | -75.0% | -2.0% | 22.3% |
Return vs Industry: DMSI underperformed the US Medical Equipment industry which returned -2% over the past year.
Return vs Market: DMSI underperformed the US Market which returned 22.3% over the past year.
Price Volatility
| DMSI volatility | |
|---|---|
| DMSI Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 7.4% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: DMSI has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DMSI's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Bruce Haglund | n/a |
Dermisonics, Inc. manufactures ultrasonic transdermal drug-delivery technologies and equipment. It primarily focuses on the development, testing, and commercialization of its active transdermal patch, called the U-Strip, that has been designed to facilitate the needle-free delivery of drugs with large molecular structures, such as Insulin into the bloodstream. The company was formerly known as Second Stage Ventures, Inc. and changed its name to Dermisonics, Inc. in October 2004.
Dermisonics, Inc. Fundamentals Summary
| DMSI fundamental statistics | |
|---|---|
| Market cap | US$1.60k |
| Earnings (TTM) | -US$22.59m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs DMSI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMSI income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$22.59m |
| Earnings | -US$22.59m |
Last Reported Earnings
Jun 30, 2007
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did DMSI perform over the long term?
See historical performance and comparison